August 8, 2025 — Leads & Copy — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, is urging its stockholders to vote FOR its reverse stock split proposal by 11:59 p.m. Eastern Time on September 4, 2025.
In a letter to stockholders, President & Chief Executive Officer Steven Lo emphasized that regaining a Nasdaq listing is a strategic imperative for Vaxart’s future and will ultimately maximize long-term value for all stockholders.
Lo stated that a Nasdaq listing offers critical advantages, including broader access to investors, greater visibility and analyst coverage, enhanced financial flexibility, improved market perception, and stronger partnership positioning.
The company has appealed Nasdaq’s suspension and is scheduled to meet with their hearings panel on August 14, 2025. Management believes relisting is contingent on conducting a reverse stock split.
Vaxart is developing oral recombinant pill vaccines. Recent progress includes rapid enrollment in its Phase 2b trial for a COVID-19 oral vaccine, positive Phase 1 results for its second-generation norovirus vaccine, and 100% protection in a preclinical trial of its avian influenza candidate.
The company has scheduled a Stockholder Fireside Chat on August 20, 2025, at 4:30 p.m. ET.
If you have any questions or need assistance with voting, please contact Vaxart’s proxy solicitation firm: Campaign Management, LLC, Toll-Free: 1-855-264-1527, Email: info@campaign-mgmt.com
Vaxart Media and Investor Relations: Matt Steinberg, FINN Partners, IR@vaxart.com, (646) 871-8481
Source: Vaxart, Inc.
